Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based Can-Fite BioPharma has started patient recruitment in a Phase 2/3 trial to investigate CF101 as a treatment of psoriasis.
Subscribe to our email newsletter
The double-blind, randomized and controlled trial is expected to compare two dose levels of CF101 to placebo.
The company anticipates to recruit around 300 patients at 17 centers.
Can-Fite CEO Fishman said the positive data from the previous Phase 2 study as well as the safety profile of CF101 indicates the potential of this innovative oral treatment for the treatment of psoriasis.